Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study - Archive ouverte HAL Access content directly
Journal Articles Clinical Colorectal Cancer Year : 2019

Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study

Frank Boudghène
  • Function : Author
Françoise Mornex
  • Function : Author
Antoine Adenis
  • Function : Author
Jean Baptiste Bachet
  • Function : Author
Véronique Vendrely
  • Function : Author
Yves François
  • Function : Author
Laurent Quero
  • Function : Author
Mathieu Coudert
  • Function : Author
Miruna Ionescu-Goga
  • Function : Author
Alexandre Tanang
  • Function : Author
Fichier principal
Vignette du fichier
S1533002818304547.pdf (359.93 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03487688 , version 1 (20-07-2022)

Licence

Attribution - NonCommercial - CC BY 4.0

Identifiers

Cite

Christophe Borg, Georges Mantion, Frank Boudghène, Françoise Mornex, François Ghiringhelli, et al.. Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study. Clinical Colorectal Cancer, 2019, 18, pp.200 - 208.e1. ⟨10.1016/j.clcc.2019.04.006⟩. ⟨hal-03487688⟩
39 View
36 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More